MEDINET Co., Ltd.
Stock Price Chart
2026/11/13 19:59 UpdatedPrice Trend
2026/11/13 19:59 UpdatedPrice & Trading Details
2026/11/13 19:59 UpdatedPRICE
TRADING
Earnings Calendar
Updated 2026/11/01Recent Earnings
| Date | EPS Est. | EPS Actual | Surprise |
|---|---|---|---|
| 2016/08/03 | ¥-2.17 | ¥-3.19 | -46.7% |
| 2016/02/04 | ¥-3.41 | ¥-4.11 | -20.6% |
| 2015/08/03 | ¥-4.39 | ¥-5.29 | -20.6% |
| 2015/05/11 | ¥-4.90 | ¥-3.87 | +21.0% |
Shareholder Composition
Updated 2026/11/01Financial Performance
2026/11/15 UpdatedRevenue & Profit
Margins
Cash Flow
Financial Health
| 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | ¥634M | ¥662M | ¥769M | ¥810M |
| Gross Profit | ¥128M | ¥98M | ¥113M | ¥110M |
| Operating Income | -¥1,333M | -¥1,426M | -¥1,385M | -¥1,445M |
| Pretax Income | -¥1,249M | -¥1,434M | -¥1,273M | -¥1,358M |
| Net Income | -¥1,254M | -¥1,438M | -¥1,277M | -¥1,362M |
| EPS | -¥6.33 | -¥6.65 | - | -¥5.15 |
| Operating Margin | -210.38% | -215.55% | -180.19% | -178.39% |
| Balance Sheet | ||||
| Total Assets | ¥6,078M | ¥5,634M | ¥5,700M | ¥4,254M |
| Total Equity | ¥5,512M | ¥5,044M | ¥5,191M | ¥3,778M |
| Total Liabilities | ¥566M | ¥590M | ¥509M | ¥476M |
| Cash | ¥4,499M | ¥4,396M | ¥4,651M | ¥2,170M |
| Interest-bearing Debt | ¥4M | ¥2M | ¥1M | ¥0M |
| Equity Ratio | 90.69% | 89.52% | 91.07% | 88.80% |
| D/E Ratio | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow | ||||
| Operating CF | -¥1,161M | -¥1,264M | -¥1,271M | -¥1,413M |
| Investing CF | -¥20M | ¥3M | ¥65M | -¥565M |
| Financing CF | ¥1,585M | ¥1,158M | ¥1,461M | -¥3M |
| Free CF | -¥1,202M | -¥1,349M | -¥1,331M | -¥1,446M |
| Efficiency | ||||
| ROE | -22.75% | -28.51% | -24.60% | -36.06% |
| ROA | -20.63% | -25.52% | -22.40% | -32.02% |
Latest IR Information
-
Notice Regarding Cessation of Domestic Development in Japan for a Regenerative Medicine Product That Received Manufacturing and Marketing Approval in India
Announces cessation of domestic development of MDNT-03. Reassesses resource allocation for the regenerative medicine business and prioritizes management resources toward the cell processing business. Will consider continuing domestic development through external partnerships. No impact on the fiscal year ending September...
Read more -
(Change in Disclosure) Change to the Use of Proceeds and Scheduled Expenditure Timing for the Issuance of Stock Acquisition Rights by Third-Party Allotment
Regarding the issuance of stock acquisition rights by third-party allotment, the use of proceeds and scheduled expenditure timing disclosed in December 2025 and March 2026 have been revised. Major changes include a reallocation of development expenses for regenerative medicine products,...
Read more -
Notice Regarding Implementation of Business Restructuring
MEDINET Co., Ltd. will implement a business restructuring to refocus resources on cell processing operations by reviewing contract manufacturing (CDMO) of specified cell-processed products supporting cancer immunocyte therapies and regenerative medicine product development. Fixed cost reductions of 300 million yen...
Read more -
Notice of Revision to Earnings Guidance for the Fiscal Year Ending September 2026
Revenue revised downward to 821 million yen (previous forecast: 943 million yen). Operating income: -1,520 million yen; Ordinary income: -1,360 million yen; Net income: -1,426 million yen. Revenue is down 12.9% versus the same period last year. Revision reasons include...
Read more -
Notice Regarding Monthly Exercise Status of the 20th Stock Acquisition Rights Allocated to a Third Party (with Exercise Price Adjustment Clause)
Stock acquisition rights exercised during the month: 10,000 units; exercise ratio against total issued for the month: 1.69%; currently unexercised: 399,499 units; number of issued shares at the end of the previous month of the applicable period: 283,667,319 shares. Exercise...
Read more
Latest News (5 items)
Company Information
About
MEDINET Co., Ltd. operates as a contract development and manufacturing organization that provides regenerative medicine and cell therapy solutions in Japan. It operates through two segments: Cell Processing Business and Regenerative Medicine Products Business.The company's solutions include technical know-how, facilities, systems, materials, professional cell-engineers, and other requirements to conduct immuno-cell therapy.It also manufactures regenerative medical/investigational and specified cell products. In addition, the company offers value chain solutions, such as personnel training, facility and equipment design, facility operations and management, preparation of standard operating procedures, logistics network, information system, purchasing and production management, quality management system, quality control and assurance, and technology transfer and process development solutions. The company serves medical institutions, research institutions, and biopharmaceutical companies. MEDINET Co., Ltd. was incorporated in 1995 and is headquartered in Tokyo, Japan.
